Lv55
1310 积分 2023-03-15 加入
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)
1天前
已完结
Effect of CD38 on B‐cell function and its role in the diagnosis and treatment of B‐cell‐related diseases
3天前
已完结
Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation
3天前
已完结
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma
3天前
已完结
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
6天前
已完结
Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
7天前
已关闭
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
7天前
已完结
Real-World Adverse Events of Isatuximab: Analysis of the FDA Adverse Event Reporting System (FAERS) Database and a Comparison with Daratumumab
7天前
已完结
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
10天前
已完结
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
10天前
已完结
BCA法检测组分百日咳疫苗中间品蛋白含量的可行性评价
2年前
已采纳
皖公网安备34019202002308
